30 Nov 2012 18:15
30 November 2012
Immunodiagnostic Systems Holdings Plc ("IDS" or "the Company" or the "Group")
Issue of Share Options
IDS (AIM: IDH), announces the issue of share options as part of an on-going programme of incentives for its employees.
Following the recommendation of the Remuneration Committee, IDS has today agreed to grant share options under the Company's Unapproved Share Option Scheme at an exercisable price of 305.3p per share to the Executive Directors and Approved Grantees (as defined in the Share Plan Rules) of the Company as follows:
Director | Exercise Price | Number of Shares |
Patrik Dahlen | 305.3p | 163,773 |
Martha Garrity | 305.3p | 44,546 |
Alain Rousseau | 305.3p | 44,546 |
Barry Hextall | 305.3p | 16,130 |
The exercise of options granted is subject to the achievement of certain performance conditions set by the Board and the options are exercisable over a period of three to ten years.
In addition to the above options granted to directors, options were granted to other Approved Grantees in respect of a further 67,745 shares.
For further information:
Immunodiagnostic Systems Holdings PLC | Tel : +44 (0)191 519 0660 |
Patrik Dahlen, Chief Executive Officer | |
Barry Hextall, Interim Finance Director | |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel | |
Dr Vijay Barathan | |
FTI Consulting | Tel : +44 (0)207 831 3113 |
Ben Atwell | |
Simon Conway | |
Mo Noonan |